KevinFGibsonMD

Pulmonology • Pittsburgh, PA

Critical Care Medicine, Pleural Disease

Professor of Medicine, Clinical , and Translational Science. University of Pittsburgh School of Medicine

Join to view full profile

Dr. Gibson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gibson's full profile

Already have an account?

Office
3601 Fifth Avenue
4th Floor Falk, Comprehensive Lung Center
Pittsburgh, PA 15213
Phone+1 412-648-6161

Education & Training

UPMC Medical EducationFellowship, Pulmonary Disease and Critical Care Medicine, 1984 - 1987
Emory University School of MedicineResidency, Internal Medicine, 1981 - 1983
Emory University School of MedicineInternship, Internal Medicine, 1980 - 1981
Rutgers Robert Wood Johnson Medical SchoolClass of 1980

Certifications & Licensure

PA State Medical License 1984 - 2026
GA State Medical License 1981 - 1985
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

Clinical Trials

Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF)
ACTIVE_NOT_RECRUITING
Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF)
RECRUITING
Dorothy P. and Richard P. Simmons Center for ILD Research Registry
RECRUITING
Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
RECRUITING
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2012 Jul 16
Completed
Phase 2
Genomic Research in Sarcoidosis Start of enrollment: 2013 May 01
Completed
Genomic Research in Alpha-1 Antitrypsin Deficiency Start of enrollment: 2013 May 01
Completed
Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jul 30
Completed
Phase 2
Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes Start of enrollment: 2014 Jan 01
Terminated
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Reply to Archontakis Barakakis and Fortis: Oxygen Supplementation Goals Beyond Correcting Ambulatory Oxygen Saturation.
Kristopher P Clark, Seyed Mehdi Nouraie, Kathleen O Lindell, Kevin F Gibson, Frank C Sciurba
Annals of the American Thoracic Society. 2025-02-13
Accelerated epigenetic aging worsens survival and mediates environmental stressors in fibrotic interstitial lung disease.
Gillian C Goobie, Daniel-Costin Marinescu, Ayodeji Adegunsoye, Jean Bourbeau, Christopher Carlsten
The European Respiratory Journal. 2025-01-30
A Ramped Treadmlll Protocol Exercise Test Identifies Higher Ambulatory Oxygen Needs in IPF and COPD.
Kristopher P Clark, Seyed Mehdi Nouraie, Kathleen O Lindell, Kevin F Gibson, Frank C Sciurba
Annals of the American Thoracic Society. 2024-11-20

Grant Support

Uptake Of Lipids In Macrophages And Type II CellsNational Heart, Lung, And Blood Institute1987–1991